Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
Mohd H. Abdul‐Aziz(The University of Queensland), Jason A. Roberts(Université de Montpellier), Despoina Koulenti(University of Thessaly), Matteo Bassetti(Ospedale Policlinico San Martino), Jordi Rello(Centre Hospitalier Universitaire de Montpellier), Steven C. Wallis(The University of Queensland), Murat Akova(Hacettepe University), Philippe Montravers(Université Claude Bernard Lyon 1), Jeffrey Lipman(The University of Queensland), George Dimοpoulos(National and Kapodistrian University of Athens), Andrew Rhodes(St George's Hospital), Kirsi‐Maija Kaukonen(Helsinki University Hospital), Jan J. De Waele(Ghent University Hospital), Claude Martin(Assistance Publique Hôpitaux de Marseille), Joel M. Dulhunty(The University of Queensland)
Cited by 164
Related Papers
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k